Get the Stockscreener App
279.97
0.08%
-0.22
Pre-market:
279.56
-0.41
-0.15%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $279.97, with a volume of 1.64M.
It is down -0.08% in the last 24 hours and down -2.87% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$280.19
Open:
$279.5
24h Volume:
1.64M
Relative Volume:
0.74
Market Cap:
$150.73B
Revenue:
$34.76B
Net Income/Loss:
$6.62B
P/E Ratio:
22.89
EPS:
12.23
Net Cash Flow:
$10.61B
1W Performance:
-2.42%
1M Performance:
-2.87%
6M Performance:
-13.82%
1Y Performance:
-14.10%
1-Day Range:
$278.78
$282.08
1-Week Range:
$277.32
$286.93
52-Week Range:
$253.30
$339.17
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
279.97 | 150.84B | 34.76B | 6.62B | 10.61B | 12.23 |
|
LLY
Lilly Eli Co
|
750.61 | 662.16B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.96 | 429.00B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.42 | 370.61B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.05 | 249.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.61 | 210.04B | 63.43B | 16.42B | 14.72B | 6.49 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Shannon Turley now part of Amgen Research’s bold new era - The Pharma Letter
Global Industrial Biomanufacturing Market Report 2026-2036: Sustainability, Synthetic Biology, and Circular Economy Drive Growth - GlobeNewswire Inc.
Eventide Asset Management LLC Raises Stake in Amgen Inc. $AMGN - MarketBeat
Nissay Asset Management Corp Japan ADV Acquires 11,694 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Curi RMB Capital LLC - MarketBeat
Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis - Benzinga
Precision Trading with Amgen Inc. (AMGN) Risk Zones - news.stocktradersdaily.com
Amgen Inc. $AMGN Shares Purchased by Kestra Investment Management LLC - MarketBeat
Amgen and Kyowa Kirin report preliminary outcomes from AD treatment trial - Yahoo Finance
Tamar Securities LLC Grows Position in Amgen Inc. $AMGN - MarketBeat
2,749 Shares in Amgen Inc. $AMGN Purchased by Talon Private Wealth LLC - MarketBeat
Amgen, Kyowa Kirin post Phase 3 data for eczema drug (AMGN) - Seeking Alpha
USS Investment Management Ltd Sells 44,026 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Alliancebernstein L.P. - MarketBeat
Federation des caisses Desjardins du Quebec Has $9.24 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen and Kyowa Kirin report positive rocatinlimab data in atopic dermatitis - Investing.com Nigeria
Advisors Asset Management Inc. Grows Stock Holdings in Amgen Inc. $AMGN - MarketBeat
If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today - AOL.com
Hancock Whitney Corp Has $20.81 Million Position in Amgen Inc. $AMGN - MarketBeat
PDT Partners LLC Cuts Stock Position in Amgen Inc. $AMGN - MarketBeat
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS - PR Newswire
Amgen Inc. $AMGN Shares Sold by Amundi - MarketBeat
Amgen Inc. $AMGN Shares Sold by Adage Capital Partners GP L.L.C. - MarketBeat
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Amgen Inc. $AMGN Shares Acquired by Cutter Capital Management LP - MarketBeat
Technical Reactions to AMGN Trends in Macro Strategies - news.stocktradersdaily.com
Amgen Inc. $AMGN Holdings Boosted by New England Asset Management Inc. - MarketBeat
Amgen Inc. $AMGN Position Boosted by NewEdge Advisors LLC - MarketBeat
Banque Transatlantique SA Has $41.26 Million Stake in Amgen Inc. $AMGN - MarketBeat
Understanding the Setup: (AMGN) and Scalable Risk - news.stocktradersdaily.com
Amgen Inc. $AMGN Shares Bought by EP Wealth Advisors LLC - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - news.stocktradersdaily.com
William Blair Reiterates a Buy on Amgen Inc (AMGN) - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Buys 36,551 Shares of Amgen Inc. $AMGN - MarketBeat
Jacobs Levy Equity Management Inc. Makes New $71.29 Million Investment in Amgen Inc. $AMGN - MarketBeat
Ameriflex Group Inc. Buys 6,882 Shares of Amgen Inc. $AMGN - MarketBeat
Calton & Associates Inc. Has $523,000 Position in Amgen Inc. $AMGN - MarketBeat
First Financial Bankshares Inc Sells 9,441 Shares of Amgen Inc. $AMGN - MarketBeat
Jump Financial LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
GW Henssler & Associates Ltd. Reduces Stake in Amgen Inc. $AMGN - MarketBeat
First Manhattan CO. LLC. Has $30.64 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Greenline Partners LLC Trims Position in Amgen Inc. $AMGN - MarketBeat
DnB Asset Management AS Buys 2,891 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Position Decreased by Flputnam Investment Management Co. - MarketBeat
Can Amgen Inc. deliver alpha2025 Performance Recap & Risk Controlled Daily Trade Plans - خودرو بانک
How liquid is Amgen Inc. stock2025 Biggest Moves & High Accuracy Swing Trade Signals - خودرو بانک
Vident Advisory LLC Has $5.56 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Royal Bank of Canada Has $1.52 Billion Position in Amgen Inc. $AMGN - MarketBeat
Panagora Asset Management Inc. Acquires 88,447 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):